Zhang Jianbin

Zhang Jianbin Ph.D., M.D. Associate Researcher, master supervisor of Zhejiang University of Traditional Chinese Medicine and Hangzhou Medical College, graduated from National University of Singapore, worked at Department of Oncology and Clinical Medicine Institute of Zhejiang Provincial People's Hospital. He has been awarded Zhejiang Provincial "Ten Thousand Talents Program" Young Top Talents, "Qianjiang Talents", "Health Innovation Talents". He was also an evaluation expert of National Natural Science Foundation of China and Zhejiang Provincial Natural Science Foundation. He joined many academic societies, including China Association of Traditional Chinese Medicine of Traditional Chinese Medicine Pharmacology Experiment Branch youth committee member, China Society of Clinical Oncology member, Chinese Immunology Association member, Zhejiang Provincial Immunology Assoication Basic Immune Branch committee member, Zhejiang Provincial Association of Tumor Etiology committee member, Zhejiang Provincial Anti-cancer Association Clinical Oncology Pharmacy committee member, Zhejiang Provincial Anti-cancer Association Oncology youth committee member, Zhejiang Provincial Medical Association Tumor Chemotherapy and Biotherapy Branch youth committee member. He has presided over or participated in 8 national and provincial projects, 5 of which have been completed. He has published more than 20 papers as the first or corresponding author in internationally renowned journals such as Autophagy, Nat Protoco, ACS Cen SCI, Angew Chem Int Ed, Cell Res, Med Res Rev, etc. Besides, he participated in editing 2 monographs, applied for 3 patents and won more than 20 academic awards. Research Interest: (1) Autophagy and tumorigenesis and its regulatory mechanism: to establish new methods for autophagy research, to reveal the regulatory mechanism of autophagy at the transcriptional, translation and post-translation levels, and to enhance the anti-tumor effect of drugs by regulating autophagy. (2) Markers and drug targets related to autophagy and tumors: to lay the foundation for the research and development of markers for tumor diagnosis, to study anti-tumor drugs with autophagy effect, and to provide new drug targets for tumor therapy. (3) Anti-tumor effect and targeting mechanism of traditional Chinese medicine: to screen and study new Chinese medicine drugs that regulate autophagy, to reveal the anti-tumor, material basis of action and targeting regulation mechanism, and to lay a foundation for the research and development of safe and effective anti-tumor new Chinese medicine/adjuvant drugs. Publications: (1) Shu Y, Sun X, Ye G, Xu M, Wu Z, Wu C, Li S, Tian J, Han H*, Zhang J*. DHOK Exerts Anti-Cancer Effect Through Autophagy Inhibition in Colorectal Cancer. Front Cell Dev Biol. 2021 Dec 17;9:760022. (2) Zhang J et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 2021 Jan;17(1):1-382. (3) Sun X, Shu Y, Xu M, Jiang J, Wang L, Wang J*, Huang D*, Zhang J*. ANXA6 suppresses the tumorigenesis of cervical cancer through autophagy induction. J. Clin Transl Med. 2020 Oct;10(6):e208. (4) Sun X, Shu Y, Yan P, Huang H, Gao R, Xu M, Lu L, Tian J*, Huang D*, Zhang J*. Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib. Cell Death Dis. 2020 Aug 24;11(8):702. (5) Sun X#, Yan P#, Zou C#, Wong YK, Shu Y, Lee YM, Zhang C, Yang ND, Wang J*, Zhang J*. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives. Med Res Rev. 2019 Apr 11. doi: 10.1002/med.21580. (6) Zhang J#, Wang J#, Zhou Z, Park JE, Wang L, Wu S, Sun X, Lu L, Wang T, Lin Q, Sze SK, Huang D*, Shen HM*. Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors. Autophagy. 2018;14(6):1043-1059. (7) Zhang J#*, Sun X#, Wang L#, Wong YK, Lee YM, Zhou C, Wu G, Zhao T, Yang L, Lu L, Zhong J, Huang D*, Wang J*. Artesunate-induced mitophagy alters cellular redox status. Redox Biol. 2018 Oct;19:263-273. (8) Wang L#, Cho YL, Tang Y, Wang J, Park JE, Wu Y, Wang C, Tong Y, Chawla R, Zhang J, Shi Y, Deng S, Lu G, Wu Y, Tan HW, Pawijit P, Lim GG, Chan HY, Zhang J, Fang L, Yu H, Liou YC, Karthik M, Bay BH, Lim KL, Sze SK, Yap CT, Shen HM*. PTEN-L is a novel protein phosphatase for ubiquitin dephosphorylation to inhibit PINK1-Parkin-mediated mitophagy. Cell Res. 2018 Aug;28(8):787-802 (9) Zhang J#*, Wang J#, Wong YK#, Sun X#, Chen Y, Wang L, Yang L, Lu L, Shen HM, Huang D*. Docetaxel enhances lysosomal function through TFEB activation. Cell Death Dis. 2018 May 23;9(6):614. (10) Wang J#, Zhang J#, Lee YM, Ng S, Shi Y, Hua ZC, Lin Q*, Shen HM*. Nonradioactive quantification of autophagic protein degradation with L-azidohomoalanine labeling. Nat Protoc. 2017 Dec;12(2):279-288.